1. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua kouté, Côte d'Ivoire.
- Author
-
Toure, Offianan A., Kouame, Menan G., Didier, Yapi J., Berenger, Ako A. A., Djerea, Khali, Genevieve, Gomez O., and Penali, Louis K.
- Subjects
DRUG therapy for malaria ,PLASMODIUM falciparum ,MEFLOQUINE ,ANTIMALARIALS ,DRUG efficacy ,RANDOMIZED controlled trials ,POLYMERASE chain reaction ,PEDIATRICS - Abstract
To test the hypothesis that Artesunate-mefloquine paediatric (AS+MEF) is as effective as Artemether-lumefantrine (AL) in treating acute uncomplicated malaria in children. In an open label, randomized controlled clinical trial, children aged 6-59 months were randomized to receive AS+MEF or AL. Both drug regimens were given for 3 days, and follow-up was for 28 days. The primary endpoint was the 28-day cure rate and was defined as proportion of patients with PCR-corrected cure rate after 28 days of follow-up. One hundred and fifty-six patients with confirmed uncomplicated P. falciparum malaria were randomly assigned to receive AS+MEF ( n = 77) or AL ( n = 79). PCR-corrected day 28 cure rates for per protocol (PP) populations were 99% for AS+MEF and 97% ( P = 1) for AL. For the intention to treat (ITT) population, cure rates were 96% for AS+MEF and 92% ( P = 0.49) for AL. Both regimens were well tolerated. AS+MEF is as effective as AL, and both combinations were efficacious and safe. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF